# Eli Lilly (LLY) — Analyst Forecast

LLY · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/lly/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 28 | 3 | 2 | 33 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $940.00 | $1,365.00 | $1,600.00 | 10 |

Last price $1,251.61 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 12, 2026 | RBC Capital | Maintained | Outperform | $1,500.00 |
| Oct 8, 2026 | Cantor Fitzgerald | Maintained | Overweight | $1,440.00 |
| Oct 7, 2026 | Morgan Stanley | Maintained | Overweight | $1,430.00 |
| Sep 28, 2026 | JP Morgan | Maintained | Overweight | $1,500.00 |
| Sep 22, 2026 | TD Cowen | Maintained | Buy | $1,250.00 |
| Sep 18, 2026 | Guggenheim | Maintained | Buy | $1,284.00 |
| Sep 10, 2026 | HSBC | Maintained | Reduce | $940.00 |
| Aug 7, 2026 | Truist Securities | Maintained | Buy | $1,376.00 |
| Aug 6, 2026 | Cantor Fitzgerald | Maintained | Overweight | $1,410.00 |
| Aug 6, 2026 | Wells Fargo | Maintained | Overweight | $1,330.00 |
| Jul 15, 2026 | Citigroup | Maintained | Buy | $1,600.00 |
| Jul 14, 2026 | Bernstein | Maintained | Outperform | $1,385.00 |
| Jul 13, 2026 | Guggenheim | Maintained | Buy | $1,273.00 |
| Jul 13, 2026 | UBS | Maintained | Buy | $1,425.00 |
| Jul 10, 2026 | B of A Securities | Maintained | Buy | $1,334.00 |
| Jul 8, 2026 | RBC Capital | Maintained | Outperform | $1,500.00 |
| Jul 8, 2026 | Morgan Stanley | Maintained | Overweight | $1,347.00 |
| Jul 8, 2026 | Truist Securities | Maintained | Buy | $1,370.00 |
| Jul 7, 2026 | JP Morgan | Maintained | Overweight | $1,400.00 |
| Jul 6, 2026 | Cantor Fitzgerald | Maintained | Overweight | $1,350.00 |

## Frequently Asked Questions

### What is the price target for LLY stock?

The average 12-month analyst price target for Eli Lilly (LLY) is $1,365.00, with a high estimate of $1,600.00 and a low of $940.00, across 10 analysts.

### Is LLY a buy, sell, or hold?

Analysts covering Eli Lilly currently average a Buy rating: 28 buy, 3 hold and 2 sell, from 33 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for LLY?

The average price target of $1,365.00 implies 9.06% upside from the last price of $1,251.61.

### What is the latest analyst rating on LLY?

On Oct 12, 2026, RBC Capital maintained Eli Lilly at Outperform with a price target of $1,500.00.

## Similar Stocks

- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock
- [VKTX](https://www.lighthorse.io/tickers/vktx) — Viking Therapeutics, Inc. - Common Stock
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [BIIB](https://www.lighthorse.io/tickers/biib) — Biogen Inc. - Common Stock
- [NVDA](https://www.lighthorse.io/tickers/nvda) — NVIDIA Corporation - Common Stock
- [INCY](https://www.lighthorse.io/tickers/incy) — Incyte Corporation - Common Stock

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).